Kyowa Kirin Co., Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 11 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Top Mutual Funds / ETFs
Updated 2026/01/11Major Holders
Updated 2026/01/11| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
3.4M | -0.77% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
2.2M | +2.37% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.6M | +1.28% | |
|
Fidelity Concord Street Trust-Fidelity International Index Fund
|
832.7K | -0.17% | |
|
iShares, Inc.-iShares MSCI Japan ETF
|
820.2K | +1.38% | |
|
iShares Trust-iShares MSCI EAFE ETF
|
799.2K | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Boston Common Asset Management, LLC
|
688.5K | -6.98% | |
|
Pacer Advisors, Inc.
|
1.9K | -10.48% |
Dividend History 4Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥60 | +3.4% |
| 2024 | ¥58 | +3.6% |
| 2023 | ¥56 | +9.8% |
| 2022 | ¥51 | +10.9% |
| 2021 | ¥46 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥352,246M | ¥398,371M | ¥442,233M | ¥495,558M |
| Gross Profit | ¥264,398M | ¥311,455M | ¥331,026M | ¥362,947M |
| Operating Income | ¥61,111M | ¥82,374M | ¥95,842M | ¥91,866M |
| Pretax Income | ¥61,167M | ¥68,660M | ¥97,436M | ¥90,991M |
| Net Income | ¥52,347M | ¥53,573M | ¥81,188M | ¥59,870M |
| EPS | ¥97.39 | ¥99.66 | ¥151.01 | ¥113.06 |
| Operating Margin | 17.35% | 20.68% | 21.67% | 18.54% |
| Balance Sheet | ||||
| Total Assets | ¥921,872M | ¥939,881M | ¥1,025,942M | ¥1,067,363M |
| Total Equity | ¥737,162M | ¥762,826M | ¥836,418M | ¥850,811M |
| Total Liabilities | ¥184,710M | ¥177,055M | ¥189,524M | ¥216,552M |
| Cash | ¥335,084M | ¥339,194M | ¥403,083M | ¥244,681M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 79.96% | 81.16% | 81.53% | 79.71% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥86,546M | ¥48,672M | ¥115,552M | ¥67,884M |
| Investing CF | -¥11,362M | -¥17,185M | -¥20,381M | -¥142,389M |
| Financing CF | -¥28,446M | -¥29,032M | -¥32,535M | -¥84,697M |
| Free CF | ¥66,780M | ¥20,006M | ¥82,700M | -¥37,384M |
| Efficiency | ||||
| ROE | 7.10% | 7.02% | 9.71% | 7.04% |
| ROA | 5.68% | 5.70% | 7.91% | 5.61% |
Latest IR Information
-
No IR information found for this company.
Searched stock code: 4151
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,635
Rating Score: - (Based on 11 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a mobilization of hematopoietic stem cells into peripheral blood for autologous blood stem cell transplantation; Libmeldy/Lenmeldy for treating metachromatic leukodystrophy; Orkedia for treatment of secondary hyperparathyroidism; and Romiplate to treat aplastic anemia. It also develops OTL-203 for the treatment of mucopolysaccharidosis type IH (hurler syndrome); KHK4083/AMG 451 to treat atopic dermatitis, prurigo nodularis, and asthma; OTL-201 for the treatment of mucopolysaccharidosis type IIIA (sanfilippo syndrome type A); ziftomenib for treating R/R acute myeloid Leukemia and acute lymphoblastic leukemia; KHK4951 for the treatment of diabetic macular edema and neovascular age-related macular degeneration; KK8123 to treat x-linked hypophosphatemia; KK2845 for the treatment of acute myeloid leukemia; KK4277 for treating systemic and cutaneous lupus erythematosus; Lumicef to treat palmoplantar pustulosis; KK2260 and KK2269 for the treatment of solid tumors; and KK8398 for the treatment of achondroplasia. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
